ABIOMED INC

Form 4

September 21, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

OMB APPROVAL

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue.

30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person * MINOGUE MICHAEL R

(First)

(Street)

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

(Middle)

ABIOMED INC [ABMD]

(Check all applicable)

C/O ABIOMED, INC..., 22

CHERRY HILL DRIVE

3. Date of Earliest Transaction

(Month/Day/Year) 09/19/2016

X Director 10% Owner Other (specify X_ Officer (give title below)

4. If Amendment, Date Original

President, CEO, Chairman 6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

DANVERS, MA 01923

(City)	(State)	(Zip) Tal	ble I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired (TransactionDisposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or		5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock \$.01 par value	09/19/2016		Code V M(7)	Amount 28,333 (7)	(D)	Price \$ 13.8	215,782	D		
Common Stock \$.01 par value	09/19/2016		M <u>(7)</u>	6,750 (7)	A	\$ 18.63	222,532	D		
Common Stock \$.01 par value	09/19/2016		M <u>(7)</u>	23,627 (7)	A	\$ 5.86	246,159	D		

Edgar Filing: ABIOMED INC - Form 4

Common Stock \$.01 par value	09/19/2016	S <u>(7)</u>	58,710 (7)	D	\$ 127	187,449	D	
Common Stock \$.01 par value	09/21/2016	M <u>(7)</u>	5,034 (7)	A	\$ 5.86	192,483	D	
Common Stock \$.01 par value	09/21/2016	S <u>(7)</u>	5,034 (7)	D	\$ 127.0739 (8)	187,449	D	
Common Stock \$.01 par value						92,788	I	By Trust
Common Stock \$.01 par value						655	I	By Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		nDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4,		6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Stock Option (right to buy) (1)	\$ 13.8	09/19/2016		M <u>(7)</u>	28	8,333 (<u>7)</u>	05/23/2009(2)	05/23/2018	Common Stock	0		
Stock Option	\$ 18.63	09/19/2016		M <u>(7)</u>	6	5,750 (7)	06/15/2009(4)	08/13/2018	Common Stock	0		

Edgar Filing: ABIOMED INC - Form 4

(right to buy) $\frac{(3)}{2}$								
Stock Option (right to buy) (3)	\$ 5.86	09/19/2016	M <u>(7)</u>	28,661 (7)	05/28/2010(2)	05/28/2019	Common Stock	0
Stock Option (right to buy) (3)	\$ 10.03				06/03/2011(2)	06/03/2020	Common Stock	0
Stock Option (Right to Buy) (3)	\$ 22.44				05/22/2013(2)	05/22/2022	Common Stock	0
Stock Option (Right to Buy) (3)	\$ 23.15				05/14/2014(2)	05/14/2024	Common stock	0
Stock Option (right to buy) (3)	\$ 21.55				05/14/2015(5)	05/14/2024	Common Stock	0
Stock Option (right to buy) (3)	\$ 66.25				05/13/2016(5)	05/13/2025	Common Stock	0
Stock Option (right to buy) (6)	\$ 99.62				05/24/2017(5)	05/24/2026	Common Stock	0

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
MINOGUE MICHAEL R C/O ABIOMED, INC., 22 CHERRY HILL DRIVE DANVERS, MA 01923	X		President, CEO, Chairman			
Signatures						
/s/ Stephen C. McEvoy (by power of attorney)		(09/21/2016			
**Signature of Reporting Person			Date			

Reporting Owners 3

Edgar Filing: ABIOMED INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant to reporting person of option to buy shares of Common Stock under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- (2) These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- (3) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- (4) These options become exercisable based on the achievement of certain performance milestones.
- (5) These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- (6) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- (7) Sale of common stock pursuant to reporting owner's 10b5-1 plan.
 - This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between
- (8) \$127.0000 and \$127.1700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.